Helix BioPharma Corp. (HBP.TO)
CAD 0.96
(0.0%)
CAD 0.96
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -1.08 Million CAD | -33.79% |
| 2023 | -808 Thousand CAD | -3.06% |
| 2022 | -784 Thousand CAD | -1768.09% |
| 2021 | 47 Thousand CAD | 101.15% |
| 2020 | -4.07 Million CAD | -1878.64% |
| 2019 | -206 Thousand CAD | 43.72% |
| 2018 | -366 Thousand CAD | 59.2% |
| 2017 | -897 Thousand CAD | 75.45% |
| 2016 | -3.65 Million CAD | 46.2% |
| 2015 | -6.79 Million CAD | 2.69% |
| 2014 | -6.98 Million CAD | -55.35% |
| 2013 | -4.49 Million CAD | 7.59% |
| 2012 | -4.86 Million CAD | 74.47% |
| 2011 | -19.04 Million CAD | -45.1% |
| 2010 | -13.12 Million CAD | 9.45% |
| 2009 | -14.49 Million CAD | 23.94% |
| 2008 | -19.05 Million CAD | -67.48% |
| 2007 | -11.37 Million CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -120 Thousand CAD | 92.69% |
| 2024 Q1 | -1.64 Million CAD | -103.09% |
| 2024 Q3 | -710 Thousand CAD | -491.67% |
| 2024 Q4 | -1.08 Million CAD | -52.25% |
| 2023 Q3 | -1.33 Million CAD | 52.9% |
| 2023 Q4 | -808 Thousand CAD | 39.25% |
| 2023 FY | -808 Thousand CAD | -3.06% |
| 2023 Q1 | -4.39 Million CAD | -460.84% |
| 2023 Q2 | -2.82 Million CAD | 35.77% |
| 2022 Q4 | -784 Thousand CAD | -178.4% |
| 2022 FY | -784 Thousand CAD | -1768.09% |
| 2022 Q1 | 1.44 Million CAD | 2974.47% |
| 2022 Q2 | 2.49 Million CAD | 72.53% |
| 2022 Q3 | 1 Million CAD | -59.89% |
| 2021 Q1 | -1.32 Million CAD | 67.39% |
| 2021 FY | 47 Thousand CAD | 101.15% |
| 2021 Q2 | -4.03 Million CAD | -203.31% |
| 2021 Q3 | -2.23 Million CAD | 44.63% |
| 2021 Q4 | 47 Thousand CAD | 102.11% |
| 2020 Q1 | -1.65 Million CAD | -700.97% |
| 2020 FY | -4.07 Million CAD | -1878.64% |
| 2020 Q4 | -4.07 Million CAD | 18.3% |
| 2020 Q2 | -2.09 Million CAD | -26.91% |
| 2020 Q3 | -4.98 Million CAD | -138.25% |
| 2019 FY | -206 Thousand CAD | 43.72% |
| 2019 Q1 | -871 Thousand CAD | -137.98% |
| 2019 Q2 | -306 Thousand CAD | 64.87% |
| 2019 Q3 | -938 Thousand CAD | -206.54% |
| 2019 Q4 | -206 Thousand CAD | 78.04% |
| 2018 Q2 | -1.64 Million CAD | 48.31% |
| 2018 Q1 | -3.17 Million CAD | -253.96% |
| 2018 FY | -366 Thousand CAD | 59.2% |
| 2018 Q4 | -366 Thousand CAD | 52.47% |
| 2018 Q3 | -770 Thousand CAD | 53.08% |
| 2017 Q1 | -2.39 Million CAD | 34.4% |
| 2017 Q2 | -1.42 Million CAD | 40.63% |
| 2017 FY | -897 Thousand CAD | 75.45% |
| 2017 Q4 | -897 Thousand CAD | 32.2% |
| 2017 Q3 | -1.32 Million CAD | 7.03% |
| 2016 Q2 | -2.52 Million CAD | 49.62% |
| 2016 FY | -3.65 Million CAD | 46.2% |
| 2016 Q4 | -3.65 Million CAD | 25.87% |
| 2016 Q3 | -4.92 Million CAD | -95.36% |
| 2016 Q1 | -5 Million CAD | 26.27% |
| 2015 Q2 | -2.72 Million CAD | 43.44% |
| 2015 FY | -6.79 Million CAD | 2.69% |
| 2015 Q1 | -4.81 Million CAD | 31.03% |
| 2015 Q4 | -6.79 Million CAD | 25.78% |
| 2015 Q3 | -9.15 Million CAD | -236.06% |
| 2014 Q3 | -2.83 Million CAD | 35.43% |
| 2014 FY | -6.98 Million CAD | -55.35% |
| 2014 Q2 | -4.38 Million CAD | -76.71% |
| 2014 Q1 | -2.48 Million CAD | 44.76% |
| 2014 Q4 | -6.98 Million CAD | -146.47% |
| 2013 Q4 | -4.49 Million CAD | 32.68% |
| 2013 FY | -4.49 Million CAD | 7.59% |
| 2013 Q1 | -3.31 Million CAD | 31.86% |
| 2013 Q2 | -8.47 Million CAD | -155.9% |
| 2013 Q3 | -6.67 Million CAD | 21.28% |
| 2012 Q3 | -5.86 Million CAD | 50.78% |
| 2012 Q2 | -11.91 Million CAD | 32.49% |
| 2012 FY | -4.86 Million CAD | 74.47% |
| 2012 Q4 | -4.86 Million CAD | 17.13% |
| 2012 Q1 | -17.65 Million CAD | 7.3% |
| 2011 FY | -19.04 Million CAD | -45.1% |
| 2011 Q4 | -19.04 Million CAD | 0.0% |
| 2010 FY | -13.12 Million CAD | 9.45% |
| 2009 FY | -14.49 Million CAD | 23.94% |
| 2008 FY | -19.05 Million CAD | -67.48% |
| 2007 FY | -11.37 Million CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Appili Therapeutics Inc. | 8.09 Million CAD | 113.362% |
| Eupraxia Pharmaceuticals Inc. | -11.72 Million CAD | 90.778% |
| Microbix Biosystems Inc. | -4.96 Million CAD | 78.211% |
| Medicenna Therapeutics Corp. | -16.98 Million CAD | 93.634% |
| Satellos Bioscience Inc. | -22.06 Million CAD | 95.101% |
| Oncolytics Biotech Inc. | -31.11 Million CAD | 96.525% |
| Sernova Corp. | -8.58 Million CAD | 87.409% |